Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
CrowdStrike FY2027 Q1 Earnings Call - AI Security Demand Drives Massive Guidance Raise
CrowdStrike delivered a blistering start to fiscal 2027, smashing expectations with record net new ARR of $256 million and 24%+ growth in ending ARR. The catalyst was the "Mythos" inflection point, wh...
- Record Q1 net new ARR of $256 million, up 32% year-over-year, exceeding the high end of guidance and driving ending ARR to $5.51 billion with 24%+ growth.
- Total revenue reached $1.39 billion, up 26% year-over-year, marking the fourth consecutive quarter of sequential growth acceleration and beating expectations.
- Free cash flow hit an all-time high of $468 million, representing a 34% margin and pushing the Rule of 40 to 59, demonstrating exceptional operational efficiency.
- +7 more takeaways
Veeva Systems Q1 2025 Earnings Call - Veeva Falcon Launches Agentic AI for Life Sciences
Veeva Systems delivered a strong Q1 2025, reporting $883 million in revenue and $395 million in non-GAAP operating income, beating guidance. The company used the call to pivot its narrative from tradi...
- Veeva reported Q1 2025 revenue of $883 million and non-GAAP operating income of $395 million, delivering results ahead of internal guidance and validating strong execution across its industry cloud portfolio.
- The company introduced Veeva Falcon, a new platform for agentic labor designed to automate high-volume, repetitive life sciences tasks such as clinical trial document processing and safety case triage, marking a strategic shift from SaaS applications to AI-driven labor.
- CEO Peter Gassner emphasized that Falcon is not a developer toolkit for custom agents but a standardized solution for the industry, leveraging Veeva’s deep domain expertise and consulting capabilities to deliver 'last mile' automation that humans cannot easily replicate.
- +7 more takeaways
Five Below Q1 2025 Earnings Call - Sales Surge 33% as Social Trends and New Store Expansion Drive Record Growth
Five Below delivered a powerhouse first quarter, with sales jumping nearly 33% to $1.3 billion and comparable sales surging 23%. The growth was fueled by a 19% increase in transactions, a 4% rise in a...
- First-quarter net sales surged nearly 33% to $1.3 billion, driven by a 23% increase in comparable sales and strong performance from 49 newly opened stores.
- Comparable sales growth was disproportionately driven by a 19% increase in transactions, with average ticket rising 4%, reflecting broad-based customer engagement.
- Adjusted EPS more than tripled to $2.22, up 158% year-over-year, while adjusted operating margin expanded 600 basis points to 12%.
- +7 more takeaways
C3.ai Fiscal Q4 2026 Earnings Call - Founder Returns to Fix
C3.ai's fiscal fourth quarter ended with a stark admission from chairman and CEO Tom Siebel: sales execution has been "unspeakably horrible," and the company is in a full-scale turnaround. Siebel retu...
- C3.ai reported total revenue of $51.6 million for fiscal Q4 2026, with subscription revenue at $48.4 million (94% of total).
- Non-GAAP gross profit was $19.3 million, yielding a 37% non-GAAP gross margin for the quarter.
- The company cut headcount from 1,075 to roughly 700, reducing annual operating costs by approximately $135 million.
- +7 more takeaways
Tilly's Q1 FY2026 Earnings Call - Sales Surge Narrows Loss as Turnaround Gains Traction
Tilly's fiscal 2026 first quarter delivered a robust 22.9% comparable net sales increase, marking its ninth consecutive month of comp growth and narrowing the net loss to $8 million from $22 million a...
- Comparable net sales surged 22.9% in Q1 FY2026, extending the comp growth streak to nine consecutive months and landing at the top of the company's outlook range.
- Net loss narrowed sharply to $8 million from $22 million year-over-year, delivering a $0.48 per share improvement and finishing one penny above the upper end of guidance.
- Gross margin improved 910 basis points to 28.9% of net sales, while product margins expanded 400 basis points, marking six consecutive quarters of product margin improvement.
- +7 more takeaways
ChargePoint Q1 FY2027 Earnings Call - Revenue Growth Returns, AI Cuts Costs, and Express Solo Charger Launches
ChargePoint delivered Q1 FY2027 revenue of $102 million, beating guidance and marking the third consecutive quarter of year-over-year growth. Non-GAAP gross margin held steady at 32%, while operating ...
- Revenue of $102 million beat the top end of guidance, up 4% year-over-year and marking the third consecutive quarter of growth.
- Non-GAAP gross margin held at 32%, with near-term stability expected as new products ramp and subscription mix normalizes.
- Operating expenses fell 4% year-over-year to $54 million, with further reductions anticipated as engineering prototyping costs taper and AI adoption scales.
- +7 more takeaways
Petco Q1 FY2026 Earnings Call - Return to Positive Comps Validates 'Reach for the Sky' Strategy
Petco delivered a pivotal first quarter for fiscal 2026, marking a decisive return to positive comparable sales growth of 0.7% while expanding profitability. The results serve as an early, tangible va...
- Petco returned to positive comparable sales growth of 0.7% in Q1 FY2026, marking a critical inflection point after sequential declines.
- Full-year guidance remains unchanged, with net sales expected to grow flat to 1.5% and adjusted EBITDA targeted between $415 million and $430 million.
- Gross margin expanded 21 basis points to 38.4%, driven by disciplined inventory management and favorable product mix shifts.
- +7 more takeaways
Vyome Holdings Q1 2026 Earnings Call - VT-1953 Pivotal Readiness Advances Amid Clean Balance Sheet
Vyome Holdings reported a quiet but strategically focused first quarter of 2026, characterized by operational discipline and a pristine capital structure. The company raised $5.29 million through a pr...
- VT-1953, the lead asset for malignant fungating wounds, advanced toward pivotal stage readiness with regulatory submissions covering manufacturing, toxicology, pharmacokinetics, and clinical development filed with the FDA.
- An orphan drug designation application for VT-1953 was submitted to the FDA, targeting an indication with no current FDA-approved therapies and an estimated $2 billion U.S. total addressable market.
- Positive Phase II clinical data for VT-1953 was presented at the AACR 2026 conference in San Diego, receiving strong feedback from independent analysts.
- +9 more takeaways
Cognyte Software Ltd. Q1 FY2027 Earnings Call - Recurring Revenue Surges as Subscription Adoption Accelerates
Cognyte delivered a solid start to fiscal 2027, with Q1 revenue rising 10.4% year-over-year to $105.5 million, driven by strong demand for its investigative analytics platform. The most notable shift ...
- Q1 FY2027 revenue grew 10.4% year-over-year to $105.5 million, reflecting steady execution and sustained demand across global markets.
- Recurring revenue increased 10% to $51.9 million, representing 49.2% of total revenue, driven by stronger-than-expected subscription adoption.
- Non-GAAP operating income surged 41.5% to $10.7 million, highlighting significant operating leverage as software revenue scales.
- +7 more takeaways
Medtronic Q4 FY2026 Earnings Call - Cardiac Ablation Solutions Drives Record Revenue Growth
Medtronic closed fiscal 2026 with its strongest top-line performance in a decade, delivering $9.8 billion in fourth-quarter revenue and $36.4 billion for the full year. The growth was primarily fueled...
- Cardiac Ablation Solutions (CAS) surged 78% in Q4, annualizing over $2 billion and driving significant top-line growth.
- Full-year 2026 revenue reached $36.4 billion, marking the strongest annual performance in a decade.
- Symplicity renal denervation is annualizing at $100 million, with strong clinical data and growing physician adoption.
- +9 more takeaways